Zobrazeno 1 - 10
of 14
pro vyhledávání: '"C. David Pendleton"'
Autor:
Yi-Hsiang Huang, Masaki Terabe, C David Pendleton, Deborah Stewart Khursigara, Tapan K Bera, Ira Pastan, Jay A Berzofsky
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e64365 (2013)
Identification of CD8(+) T cell epitopes that can induce T cells to kill tumor cells is a fundamental step for development of a peptide cancer vaccine. POTE protein is a newly identified cancer antigen that was found to be expressed in a wide variety
Externí odkaz:
https://doaj.org/article/e287a5b843b0419f8d53a1ca0ea0bf16
Autor:
Brian Stegman, Martin O. Ota, C. David Pendleton, Diane E. Griffin, Donald S. Burke, Chien Hsiung Pan, Sang Kon Oh, Jay A. Berzofsky
Publikováno v:
Virology. 352:390-399
Natural infection and vaccination with a live-attenuated measles virus (MV) induce CD8+ T-cell-mediated immune responses that may play a central role in controlling MV infection. In this study, we show that newly identified human HLA-A2 epitopes from
Autor:
Sujatha Iyengar, Jay A. Berzofsky, Thomas Elaine K, Takahiro Okazaki, C. David Pendleton, David C. Schwartz, Pablo Sarobe, Clayton Harro
Publikováno v:
Dadun. Depósito Académico Digital de la Universidad de Navarra
instname
instname
Virus-specific CD4+ T cell help and CD8+ cytotoxic T cell responses are critical for maintenance of effective immunity in chronic viral infections. The importance of CD4+ T cells has been documented in HIV infection. To investigate whether a stronger
Autor:
Lee J. Helman, C. David Pendleton, Jay A. Berzofsky, Crystal L. Mackall, Leon T. van den Broeke
Publikováno v:
Cancer Research. 66:1818-1823
Fusion proteins created by chromosomal translocations in tumors can create neoantigenic determinants at the breakpoint, which are unique to the tumor cells but shared by the vast majority of tumors of that histologic type. If the fusion protein is re
Autor:
Michael Stipanov, Jay A. Berzofsky, M. Charles Smith, I. Frank Ciernik, Denise Kavanaugh, Charley Carter, Elizabeth J. Read, David Contois, Morris I. Kelsey, Sorena Nadaf, Burkhardt Seifert, Lois E. Top, John D. Minna, C. David Pendleton, Bruce E. Johnson, Michael J. Kelley, David P. Carbone, Jay Greenblatt, V. Ellen Maher
Publikováno v:
Journal of Clinical Oncology. 23:5099-5107
PurposeTo determine the ability to induce tumor-specific immunity with individual mutant K-ras–or p53-derived peptides and to monitor clinical outcome.Patients and MethodsPatients in varying stages of disease underwent genetic analysis for mutation
Autor:
Graham R. Leggatt, Anne Hosmalin, C. David Pendleton, Anita Kumar, Stephen Hoffman, Jay A. Berzofsky
Publikováno v:
The Journal of Immunology. 161:4728-4735
A minimal, nonamer epitope (TEMEKEGKI) from the reverse transcriptase protein of HIV-1, restricted by H-2Kk, was identified and the function of individual residues determined. Besides classical anchor residues at positions 2 and 9, methionine at posi
Autor:
Warren Strober, Linda S. Wyatt, Patricia L. Earl, Brian L. Kelsall, Jay A. Berzofsky, Jeffrey D. Ahlers, Bernard Moss, C. David Pendleton, Igor M. Belyakov
Publikováno v:
Journal of Virology. 72:8264-8272
To improve the safety of recombinant vaccinia virus vaccines, modified vaccinia virus Ankara (MVA) has been employed, because it has a replication defect in most mammalian cells. Here we apply MVA to human immunodeficiency virus type 1 (HIV-1) vaccin
Autor:
Jay A. Berzofsky, Martha A. Alexander-Miller, C. David Pendleton, Taku Tsukui, John E. Coligan, Kenneth C. Parker
Publikováno v:
International Immunology. 8:641-649
P18IIIB is a highly immunogenic peptide from the V3 loop of the HIV-1 gp160 envelope protein that is presented promiscuously by multiple class I MHC molecules. Understanding the molecular basis for promiscuous presentation may have many practical app
Autor:
Claude Kasten-Sportes, John Phillips, Jay A. Berzofsky, W. Marston Linehan, Yoram Reiter, Tapan K. Bera, Malka Epel, Ira Pastan, Sangkon Oh, Anu Bhattacharyya, C. David Pendleton, Masaki Terabe
Publikováno v:
Cancer research. 64(7)
Vaccine therapy for prostate and breast cancer may have potential for treating these major causes of death in males and females, respectively. Critical to the development of tumor-specific vaccines is finding and characterizing novel antigens to be r
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 171(5)
HIV epitopes may have developed to be poor immunogens. As a counterapproach HIV vaccine strategy, we used epitope enhancement of a conserved HIV reverse transcriptase (RT) epitope for induction of antiviral protection in HLA-A2-transgenic mice mediat